SARS-CoV-2 IgM ELISA Kit: A valuable tool to study COVID-19 epidemiology

For identifying the early immune response to SARS-CoV-2 infection
MILPITAS, Calif. - Sept. 24, 2020 - PRLog -- BioVision's SARS-CoV-2 IgM ELISA Kit is an enzyme-linked immunosorbent assay intended for identifying the early immune response to SARS-CoV-2 infection. The assay uses the spike protein S1 subunit as bait to capture anti-SARS-CoV-2 antibodies in diluted plasma or serum samples. Subsequent reaction with an enzyme-labeled anti-human-IgM conjugate and a colorimetric substrate generates color, which is proportional to the amount of anti-S1 antibodies. The presence of anti-SARS-CoV-2 S1 IgM antibodies is determined by comparing the OD450 nm reading of the sample to the OD450 nm reading of the negative control serum. A positive reaction suggests recent infection, as IgM antibodies are the first to appear following exposure and are generally detectable a few days after infection. Positive control serum containing a recombinant human monoclonal anti-S1 IgM antibody is included in the kit for validation. The assay is a quick, easy and accurate method for determination of recent SARS-CoV-2 infection that does not require collection or handling of infectious virus. This kit is a valuable tool to study COVID-19 epidemiology, prevalence and morbidity.

Figures: (a) Detection of Anti-SARS-CoV-2 IgM antibodies in serum samples (dilution 1:100). COVID-19 patient serum samples were obtained from individuals that had a positive test for SARS-CoV-2 viral RNA by RT-PCR from nasopharyngeal swab specimen. All patient serum samples were collected at 5-20 days following PCR confirmation of SARS-CoV-2 infection. Healthy serum was donorpooled off-the-clot serum obtained from healthy individuals prior to the COVID-19 pandemic. The response from Negative Control Serum was used to determine the cutoff for positivity (indicated by the dashed line). (b) Serial Dilutions of COVID-19 patient sera versus healthy serum. Calculated AUC values for COVID-19 patient samples were 1.96-, 9.98-, 3.69- and 14.43-fold greater than that of prepandemic healthy human serum, respectively. Data presented are mean ± SD of triplicate or greater wells.

For more information on this kit, visit:

Media Contact
Marketing BioVision
408-493-1800 ext 224
Email:*** Email Verified
Location:Milpitas - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
BioVision, Inc. News
Most Viewed
Daily News

Like PRLog?
Click to Share